Get to know us at
BioReperia
Read about our company and get to know who we are
Why
BioReperia?
We care
about patients
BioReperia is a privately owned company that was founded in September 2015 based on technology developed at Linköping University in Sweden.
BioReperia offers innovative solutions for cancer treatment and drug discovery. Our CE-certified Zebrafish Tumor Xenograft platform, ZTX®PREDICT, provides accurate predictions of cancer drug efficacy within 5 days, aiding personalized treatment planning and improving patient outcomes. As a pioneer in metastatic risk assessment, ZTX®PREDICT sets a new standard in diagnostics.
Since 2015, our ZTX®ONCOLEADS platform has helped pharmaceutical companies accelerate drug discovery, particularly for immunotherapies and targeted therapies, reducing costs and enhancing clinical trial success.
Serving clients worldwide, BioReperia is advancing oncology research and improving patient access to life-saving treatments.
The meaning
behind our name
Reperia is derived from the Latin word ‘reperio’ meaning discovery or research and was used by ancient Roman scientists to describe their work with identifying new ways of treating diseases.